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INTRODUCTION
Radical prostatectomy (RP) is used as a curative therapy for pa-
tients with prostate cancer (PCa). RP has been shown to confer 
excellent oncological control and long-term survival for local-
ized PCa by reducing the risk of local tumor progression and 
metastasis.1 RP can be used as an option for various stages of 
PCa, from localized to high-risk disease.2 Furthermore, evi-
dence suggests a survival benefit when RP is included as part 
of multimodal therapy in patients with oligometastatic PCa.3
Androgen-deprivation therapy (ADT) is the standard therapy 
for patients with metastatic PCa and it can also be employed 
as part of multimodal therapy following RP. For patients ex-
hibiting adverse pathological features, ADT can be used with 
radiation therapy (RT) to improve cancer-specific survival 
(CSS) and overall survival (OS).4-8 ADT can also be adminis-
tered after prostate-specific antigen (PSA) recurrence with RT, 
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depending on the presence of metastasis, as a salvage treat-
ment.9,10 However, the optimal value of PSA and the disease 
landscape in which ADT should be administered are still a 
matter of debate.
Early initiation of ADT may be superior to delayed ADT in 
terms of short-term oncological outcomes; however, the ben-
efit of early ADT is unclear in terms of CSS or OS outcomes.2 
Adverse effects of ADT cannot be overlooked. Moreover, the 
advent of non-metastatic castration-resistant disease may be 
attributed to early administration of ADT.11 On the other hand, 
12% of patients receiving RP for localized or locally advanced 
PCa are destined to develop metastasis during the median 
follow-up of 2.2 years, and early ADT may be a feasible option 
to delay metastatic progression.12,13
Contemporary guidelines do not indicate the optimal tim-
ing for administering ADT following RP, and state that treat-
ment should be individualized depending on PSA kinetic pa-
rameters such as PSA doubling time (PSADT), PSA velocity 
(PSAV), patient anxiety, underlying comorbidities, and life ex-
pectancy.2 Indeed, this disease spectrum poses uncertainty for 
both patients and physicians and warrants investigation. The 
primary endpoint of our study was the impact of early versus 
delayed ADT on survival outcomes in patients with localized 
or locally advanced PCa who received RP and later developed 
metastasis. The secondary study endpoint was the definition 
of a specific level of PSA-related parameters that can be uti-
lized to select candidates for early initiation of ADT.
MATERIALS AND METHODS
Patient selection
This multicenter study evaluated data from 923 consecutive 
patients with non-metastatic, localized or locally advanced 
PCa who received adjuvant or salvage RT for PSA-only recur-
rence following RP between January 2006 and December 2012. 
Among these patients, 69 (7.5%) patients who later developed 
distant metastasis were selected for analysis (Fig. 1). The 
study’s protocol was approved by the Institutional Ethics Com-
mittee (2017-0186-001).
Data collection
The patients’ clinicopathological characteristics were retrieved 
from the institutional electronic medical records database. The 
variables included age, body mass index, Eastern Cooperative 
Oncology Group Performance Status Scale, National Compre-
hensive Cancer Network (NCCN) risk category, time to PSA 
recurrence, time from PSA recurrence to ADT initiation, path-
ological Gleason score and stage, preoperative PSA level, PSA 
nadir at RP, PSA level at ADT initiation, PSAV and PSADT be-
fore ADT, PSA nadir after ADT, and time to PSA nadir.
PCa staging was determined according to the 7th version of 
the American Joint Committee on Cancer TNM system. Cas-
tration-resistant prostate cancer (CRPC) was defined as the 
progression of disease or an increase in serum PSA using the 
Prostate Cancer Working Group 2 criteria.14 The progression of 
disease was diagnosed based on a continuous increase in se-
rum PSA levels, new symptom development, or a metastatic 
lesion detected during ADT using radiographic imaging.
For all patients, the status of survival and cause of death were 
investigated using institutional electronic medical records, the 
National Cancer Registry Database, or the Social Security 
Death Index. Death was attributed to PCa if evidence of pro-
gressive metastatic CRPC was present, PCa was listed on the 
death certificate as the cause of death, or if the patient died of 
complications of PCa treatment.
Treatments
Robot-assisted laparoscopic RP was recommended for pa-
tients who were determined to be reasonable surgical candi-
dates and desired surgical treatment. Surgery was performed 
with the extent of pelvic lymph node dissection being based 
Patients with localized/locally advanced PCa treated with 




No distant metastases 
(n=854)
PSA at ADT (≥2 ng/mL) 
(n=38)
PSA at ADT (<2 ng/mL) 
(n=31)
Fig. 1. Flowchart of patient selection. ADT, androgen-deprivation therapy; PCa, prostate cancer; PSA, prostate-specific antigen; RP, radical prostatectomy; 
RT, radiation therapy.
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upon the risk category of the patient.
RT was delivered to the prostatic fossa with defined margins 
according to the guidelines of the European Organization for 
Research and Treatment of Cancer.15 At both institutions, RT 
consisted of 3D conformal RT from 2000 to 2007 and intensity-
modulated external beam RT from 2007 to 2016. The medi-
an RT dose delivered was 6300 cGy [interquartile range (IQR) 
6300–6300 cGy].
ADT included luteinizing hormone-releasing hormone ag-
onists only or combined androgen blockade. In the subset of 
patients who received concurrent ADT with RT, ADT was ad-
ministered for 6 to 24 months according to the physician’s 
discretion. In the subset of patients who received ADT as an 
adjuvant setting, ADT was administered to patients with a 
PSA persistence or an increasing PSA following RT. All pa-
tients included in our study cohort received continuous ADT, 
and no patient received intermittent ADT. For patients who 
progressed to CRPC, lifelong ADT was performed until death 
or last follow-up. All patients received the standard-of-care 
according to contemporary guidelines until death or the last 
follow-up.
Study endpoints
The primary endpoint was progression to CRPC-free survival 
and CSS. The secondary endpoint was specific levels of PSA-
related parameters that can be utilized to select candidates for 
the initiation of ADT.
Statistical analysis
Chi-square test and ANOVA were used to compare two or more 
variables, and Mann-Whitney U test was used for the analysis 
of continuous variables. Survival analysis was evaluated and 
compared using the Kaplan-Meier method and compared with 
the log-rank test.
The prognostic significances of PSAV and PSADT before 
ADT, PSA at ADT, and PSA nadir after ADT were dichoto-
mized at 2 ng/mL/year, 12 months, 2 ng/mL, and 1 ng/mL, 
respectively. These optimal cut-off values were based on pre-
defined values and according to sensitivity analysis using 
Youden’s Index. Multivariate analyses were performed with 
Cox-proportional hazards regression models to adjust for po-
tential confounders. The following covariates were included: 
age, body mass index, Eastern Cooperative Oncology Group 
Performance Status Scale, pathological Gleason score and 
stage, time to PSA recurrence, time from PSA recurrence to 
ADT initiation, preoperative PSA level, PSA nadir at RP, PSAV 
and PSADT before ADT, PSA level at ADT initiation, PSA nadir 
following ADT, and time to PSA nadir. All statistical analyses 
were performed using IBM SPSS software (version 21.0; IBM 
Corporation, Armonk, NY, USA). Differences with a p-value of 
<0.05 were considered statistically significant.
RESULTS
Patient characteristics
Patient demographics and clinicopathological features of 
groups stratified by the PSA level at ADT of 2 ng/mL are pre-
sented in Table 1. There were no significant differences be-
tween the two groups regarding the patients’ age, body mass 
index, performance status, preoperative PSA level, NCCN risk 
category, pathological Gleason score and stage, type of RT, 
and PSAV and PSADT before ADT. There were no differences 
in patient distributions according to the type of RT or timing 
of ADT administration.
Prognosticators of survival
Cox proportional hazards regression analyses of predictors for 
progression to CRPC are presented in Table 2. On univariate 
analyses, PSA at ADT initiation ≥2 ng/mL (p=0.032) and PSA 
nadir following ADT ≥1 ng/mL (p=0.016) were significantly 
associated with an increased risk of progression to CRPC. On 
multivariate analyses, PSA at ADT initiation ≥2 ng/mL was a 
marginally significant prognosticator (p=0.051).
Cox proportional hazards regression analyses of predictors 
for cancer-specific mortality are presented in Table 3. On uni-
variate analyses, Gleason score ≥8 (p=0.024), PSA at ADT ini-
tiation ≥2 ng/mL (p=0.015), and PSA nadir following ADT ≥1 
ng/mL (p=0.019) were significantly associated with an in-
creased risk of cancer-specific mortality. On multivariate 
analyses, PSA at ADT initiation ≥2 ng/mL was an independent 
predictor of cancer-specific mortality (p=0.047).
Patients’ age, body mass index, grade and stage, preopera-
tive PSA, PSA nadir at RP, PSAV and PSADT prior to ADT, and 
time to PSA nadir following ADT were not independently as-
sociated with progression to CRPC and cancer-specific mor-
tality.
Survival outcome
Survival outcomes were compared according to the PSA level 
at ADT, which was stratified at 2 ng/mL (Table 4). During the 
median follow-up of 81.0 (IQR 54.2–115.7) months, patients 
who received ADT at PSA <2 ng/mL had significantly higher 
CSS rates than men who received ADT at PSA ≥2 ng/mL (p= 
0.002) (Fig. 2). Progression to CRPC-free survival was compa-
rable between the two groups (p=0.331) (Fig. 3).
DISCUSSION
ADT is a treatment option for all stages of PCa, from localized 
disease with a high risk of recurrence to castration-resistant 
disease.16 Following RP, ADT can be used as an adjuvant ther-
apy combined with RT to maximize survival outcomes in pa-
tients exhibiting adverse pathological features. Previous re-
ports have suggested that the use of ADT in this clinical 
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scenario may improve CSS and OS.4-9 ADT can also be admin-
istered with RT at PSA recurrence, depending on the presence 
of metastasis, as a salvage treatment option, which may result 
in clinical benefit.9 However, the optimal level of PSA at which 
ADT should be administered remains controversial. In this 
study, we observed that delaying ADT following PSA elevation 
beyond 2 ng/mL was associated with an increased risk of pro-
gression to CRPC and cancer-specific mortality.
In our study, a PSA cut-off value of 2 ng/mL based on Youden 
sensitivity analysis was revealed to be a prognosticator for CSS 
in patients with PSA-only recurrent PCa following RP. Previ-
ous studies report varying indications for initiating ADT fol-
lowing RP. Amling, et al.17 suggested that a PSA value of greater 
than 0.4 ng/mL should be used to define PSA recurrence, since 
this cut-off point is associated with an increased risk of bio-
chemical and/or clinical progression. Freedland, et al.18 report-
ed that the risk of the need for secondary treatment following 
PSA recurrence depends on the cut-off value of PSA. Based on 
the finding that patients with a postoperative PSA greater than 
0.2 ng/mL had a 100% 3-year risk of PSA progression, this cut-
off point was suggested to be an indicator to initiate treatment. 
Siddiqui, et al.19 suggested that adjuvant ADT within 90 days 
after RP improves CSS and systemic progression-free survival 
in node-negative patients. However, there were no differences 
in systemic progression-free survival or CSS between patients 
who began ADT at PSA values of 0.4, 1.0, and 2.0 ng/mL. A ran-
Table 1. Clinicopathological Characteristics of Patients with Localized Prostate Cancer Who Underwent Radical Prostatectomy and Later Developed 
Metastasis
Overall
PSA level at ADT initiation
p value
<2 ng/mL ≥2 ng/mL
N 69 31 (45.0) 38 (55.0) NS
Age (yr) 69.0 (67.0–72.5) 68.5 (61.5–75.8) 71.0 (69.0–70.5) 0.861
BMI (kg/m2) 22.9 (21.9–26.8) 21.9 (20.6–26.1) 23.1 (21.7–27.3) 0.765
ECOG PS 0.644
≤1 60 (86.9) 27 (87.1) 33 (86.8)
≥2   9 (13.1)   4 (12.9)   5 (13.2)
Preoperative PSA (ng/mL) 17.4 (7.4–50.0) 20.0 (9.3–43.0) 14.8 (8.6–75.5) 0.256
PSA velocity 0.191
≥2 ng/mL/year 38 (55.1) 16 (51.6) 22 (57.9)
<2 ng/mL/year 31 (44.9) 15 (48.4) 16 (42.1)
PSA doubling time 0.246
≥12 months 33 (47.8) 14 (45.2) 19 (50.0)
<12 months 36 (52.2) 17 (54.8) 19 (50.0)
Time from PSA recurrence to ADT initiation (months) 4.0 (2.0–9.0) 3.0 (1.0–16.5) 4.5 (2.8–6.8) 0.804
NCCN risk category 0.197
Low   7 (10.1)   5 (16.2) 2 (5.3)
Intermediate 18 (26.1)   9 (29.0)   9 (23.7)
High 44 (63.8) 17 (54.8) 27 (71.0)
Gleason score 0.582
≤6 13 (18.8)   7 (22.6)   6 (15.8)
7 15 (21.7)   8 (25.8)   7 (18.4)
≥8 41 (59.5) 16 (51.6) 25 (65.8)
Pathological stage 0.541
T2 12 (17.4)   7 (22.6)   5 (13.1)
T3 47 (68.1) 20 (64.5) 27 (71.1)
T4 10 (14.5)   4 (12.9)   6 (15.8)
Type of radiation therapy 0.158
Adjuvant 11 (15.9)   5 (16.1) 6 (15.8)
Salvage 58 (84.1) 26 (83.9) 32 (84.2)
Timing of ADT administration 0.835
Concurrent with radiation therapy 37 (53.6) 17 (54.8) 20 (52.6)
Adjuvant 32 (46.4) 14 (45.2) 18 (47.4)
ADT, androgen-deprivation therapy; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; NCCN, National Comprehensive 
Cancer Network; PSA, prostate-specific antigen.
Data are expressed as median (interquartile range) and number (%).
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domized trial investigated the efficacy of immediate ADT ver-
sus delayed ADT after randomization among patients with PSA 
recurrence who were considered ineligible for curative treat-
ment.20 In the overall group, immediate ADT was associated 
with improvements in OS and time to clinical progression. How-
ever, no improvement of OS was observed in patients with PSA 
recurrence following curative therapy. A common limitation of 
these studies was that not all patients had received RT as mul-
timodal therapy, as suggested by contemporary guidelines. In 
our study, all of the patients were treated with RT in an adjuvant 
or salvage setting according to the guidelines, which implies the 
generalizability of our data.
In our study, PSAV, PSADT, and Gleason score were not in-
dependently associated with survival endpoints. Contrarily, 
studies have recommended that these parameters be utilized 
to decide on the timing of ADT at PSA-recurrence following 
RP.20-30 Van den Bergh, et al.22 reported in a systematic review 
that early ADT cannot be recommended as the standard-of-care 
for PSA recurrence or local recurrence, and that ADT should be 
reserved for patients with the highest risk of disease progres-
sion, defined as short PSADT of less than 6–12 months or Glea-
son score of greater than 8. Algarra, et al.23 reported seminal 
vesical involvement, PSAV of greater than 0.84 ng/mL/year, and 
PSADT to be considered as adverse features associated with 
disease progression in patients who received ADT at PSA recur-
rence. In a cohort of patients with mainly high-risk disease, 
faster PSADT, higher Gleason score, and early intervention 
were associated with a lower risk of CSS.26 The significance of 
PSADT was consistent in patients receiving intermittent ADT, 
in which a PSADT and PSA nadir of less than 1 ng/mL during 
the first cycle was associated with improvement in CRPC-free 
survival.25 On the other hand, studies have reported higher 
PSA and PSA nadir after starting ADT, rather than PSADT or 
PSAV, to be significant indicators for CSS.29,30 As seen in these 
studies, the parameters utilized for clinical endpoints were in-
consistent, which defers a definite conclusion. Moreover, vari-
Table 2. Cox-Regression Models for the Association of Risk Factors with Progression to Castration-Resistance
Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Age 0.951 0.884–1.023 0.173
BMI 1.085 0.928–1.269 0.306
ECOG PS
≤1 1 Reference
≥2 0.504 0.139–1.829 0.298
Gleason score
≤7 1 Reference
≥8 2.202 0.894–5.424 0.086
Pathological stage
≤T2 1 Reference
≥T3 0.779 0.168–3.607 0.749
Time to PSA recurrence 0.938 0.870–1.011 0.092
Time from PSA recurrence to ADT initiation 1.033 0.741–1.442 0.847
Preoperative PSA 1.004 0.994–1.015 0.408
PSA nadir at RP 2.113 0.847–5.270 0.109
PSAV before ADT
<2 ng/mL/year 1 Reference
≥2 ng/mL/year 1.487 0.604–3.657 0.388
PSADT before ADT
<12 months 1 Reference
≥12 months 0.983 0.961–1.005 0.134
PSA at ADT initiation
<2 ng/mL 1 Reference
≥2 ng/mL 3.184 1.104–9.179 0.032 3.934 0.994–15.57 0.051
PSA nadir following ADT
<1 ng/mL 1 Reference
≥1 ng/mL 3.792 1.286–11.19 0.016 1.301 0.669–4.382 0.511
Time to PSA nadir 0.955 0.872–1.046 0.324
ADT, androgen-deprivation therapy; BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, haz-
ards ratio; PSA, prostate-specific antigen; PSADT, prostate-specific antigen doubling time; PSAV, prostate-specific antigen velocity; RP, radical prostatectomy.
657
Hyun Kyu Ahn, et al.
https://doi.org/10.3349/ymj.2020.61.8.652
ous cut-off points were used for stratification of PSADT or 
PSAV, if they were not evaluated as continuous variables. To 
our knowledge, the present study is the first to suggest an op-
timal cut-off point of PSA to initiate ADT to confer CSS benefit 
in patients who underwent RT after PSA-only recurrence. Our 
results are meaningful since the patients included in our study 
were a homogeneous group who were treated with RT and 
standard care according to contemporary guidelines until 
death or last follow-up.
Based on accumulating evidence, there has been a paradigm 
shift in considering aggressive treatments targeted at both the 
primary tumor and metastatic lesions of PCa to avoid or delay 
the need for palliative treatments and to achieve maximal 
survival benefit.3 PSA recurrence is the most common pattern 
of disease relapse following RP, observed in up to 35% of pa-
tients.31 In an era of aggressive treatments for oligometastatic 
PCa, it is certain that more patients will experience postopera-
tive PSA recurrence and would be candidates for ADT. We be-
lieve that our findings provide relevant evidence for the deci-
sion-making and patient stratification in future clinical trials.
Table 3. Cox-Regression Models for the Association of Risk Factors with Progression to Cancer-Specific Mortality
Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Age 1.036 0.922–1.165 0.552
BMI 0.994 0.767–1.288 0.963
ECOG PS
≤1 1 Reference
≥2 3.063 0.651–14.42 0.157
Gleason score
≤7 1 Reference
≥8 5.743 1.264–26.09 0.024 3.844 0.834–17.72 0.084
Pathological stage
≤T2 1 Reference
≥T3 2.939 0.896–9.631 0.075
Time to PSA recurrence 0.864 0.691–1.081 0.201
Time from PSA recurrence to ADT initiation 0.955 0.737–1.226 0.688
Preoperative PSA 0.994 0.981–1.008 0.376
PSA nadir at RP 1.802 0.619–5.240 0.281
PSAV before ADT
<2 ng/mL/year 1 Reference
≥2 ng/mL/year 0.940 0.268–3.298 0.923
PSADT before ADT
<12 months 1 Reference
≥12 months 0.996 0.971–1.021 0.737
PSA at ADT initiation
<2 ng/mL 1 Reference
≥2 ng/mL 6.495 1.432–29.47 0.015 5.211 1.076–25.23 0.047
PSA nadir following ADT
<1 ng/mL 1 Reference
≥1 ng/mL 4.353 1.276–14.86 0.019 2.234 0.624–8.003 0.217
Time to PSA nadir 0.972 0.864–1.092 0.631
ADT, androgen-deprivation therapy; BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, haz-
ards ratio; PSA, prostate-specific antigen; PSADT, prostate-specific antigen doubling time; PSAV, prostate-specific antigen velocity; RP, radical prostatectomy.
Table 4. Oncological Outcomes of Patients with Localized Prostate 
Cancer who Underwent Radical Prostatectomy and Later Developed 
Metastasis
PSA at ADT p 
value<2 ng/mL ≥2 ng/mL
Time to metastasis (months) 33.5 (14.0–42.3) 31.2 (12.3–41.1) 0.971
Metastatic site
Bone 27 (87.1) 33 (86.8) 0.468
Lymph nodes   3 (10.0)   5 (13.2) 0.621
Viscera 2 (6.5) 3 (7.9) 0.133
CRPC (%) 17 (53.1) 30 (51.7) 0.548
Time to CRPC (months) 55.5 (35.2–97.8) 42.5 (32.3–73.8) 0.051
CRPC-free progression, 5 yr (%) 70.8 64.7 0.311
Death 7 (21.9) 22 (37.9) 0.001
Time to CSM (months) 72.0 (45.0–108.9) 65.0 (52.5–90.0) 0.045
CSS, 5 yr (%) 86.1 68.7 0.002
Follow-up (months) 83.5 (70.5–118.5) 78 (52.4–94.0) 0.074
ADT, androgen-deprivation therapy; CRPC, castration-resistant prostate can-
cer; CSM, cancer-specific mortality; CSS, cancer-specific survival; PSA, pros-
tate-specific antigen.
Data are expressed as median (interquartile range) and number (%).
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The strengths of our study were the inclusion of detailed PSA 
kinetic data, comorbidities, performance status, and clinico-
pathological data that were available for all patients. At the same 
time, we acknowledge several limitations: first, our study was 
limited by its retrospective design and the sampling intervals 
used to estimate PSA kinetics were not standardized. More-
over, the administration of ADT may not have been well-struc-
tured among physicians. Second, the potential existence of bias 
regarding subgroup differences may have confounded the re-
sults, although there were no statistically significant differenc-
es between the two groups stratified by the level of PSA at ADT. 
Third, patient and physician preferences affected the imple-
mentation of specific treatments, including the timing of ADT 
and RT. Finally, the OS may serve as a proxy for survival out-
comes. However, we chose to use CSS as the endpoint, as our 
study population included patients who were relatively older 
and of lower performance status compared to the general pop-
ulation. Since OS may be affected by competing risks, we con-
sidered that this survival endpoint might not reliably reflect 
prostate CSS benefits conferred by early ADT.
Early ADT at the PSA level of less than 2 ng/mL confers a 
CSS benefit in patients with localized or locally advanced PCa 
who were previously treated with RP. Future larger-scale anal-
yses are warranted to validate our results.
ACKNOWLEDGEMENTS
This study was supported by a Research Grant from the Na-
tional Research Foundation of Korea (2020R1F1A1073833).
AUTHOR CONTRIBUTIONS
Conceptualization: Kyo Chul Koo. Data curation: Kwang Suk Lee and 
Daeho Kim. Formal analysis: Hyun Kyu Ahn. Funding acquisition: 
Kyo Chul Koo. Investigation: Hyun Kyu Ahn and Kyo Chul Koo. Meth-
odology: Hyun Kyu Ahn and Kwang Suk Lee. Project administration: 
Koon Ho Rha, Sung Joon Hong, and Byung Ha Chung. Resources: 
Koon Ho Rha and Sung Joon Hong. Supervision: Kyo Chul Koo. Writ-
ing—original draft: Hyun Kyu Ahn. Writing—review & editing: Kyo 
Chul Koo. Approval of final manuscript: all authors.
ORCID iDs
Hyun Kyu Ahn https://orcid.org/0000-0002-1996-6249
Kwang Suk Lee https://orcid.org/0000-0002-7961-8393
Daeho Kim https://orcid.org/0000-0003-2314-8625
Koon Ho Rha https://orcid.org/0000-0001-8588-7584
Sung Joon Hong https://orcid.org/0000-0001-9869-065X
Byung Ha Chung https://orcid.org/0000-0001-9817-3660
Kyo Chul Koo https://orcid.org/0000-0001-7303-6256
REFERENCES
1. Tan L, Wang LL, Ranasinghe W, Persad R, Bolton D, Lawrentschuk 
N, et al. Survival outcomes of younger men (< 55 years) undergo-
ing radical prostatectomy. Prostate Int 2018;6:31-5.
2. Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, 
Dorff T, et al. Prostate cancer, version 2.2019, NCCN clinical prac-
tice guidelines in oncology. J Natl Compr Canc Netw 2019;17:479-
505.
3. Koo KC, Dasgupta P. Treatment of oligometastatic hormone-sen-
sitive prostate cancer: a comprehensive review. Yonsei Med J 2018; 
59:567-79.







0                         50                       100                      150                      200
p=0.002
  PSA at ADT ≥2 ng/mL












0                         50                       100                      150                      200
p=0.331
  PSA at ADT ≥2 ng/mL




















Fig. 2. Kaplan-Meier curves showing CSS, stratified by the PSA level at 
ADT of 2 ng/mL. ADT, androgen-deprivation therapy; CSS, cancer-spe-
cific survival; PSA, prostate-specific antigen.
Fig. 3. Kaplan-Meier curves showing progression to CRPC-free survival, 
stratified by the PSA level at ADT of 2 ng/mL. ADT, androgen-depriva-
tion therapy; CRPC, castration-resistance prostate cancer; PSA, pros-
tate-specific antigen.
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